BioScrip Agrees To Pay $15M In FCA Kickback Suit
BioScrip Inc. has agreed to pay $15 million to exit a False Claims Act whistleblower suit alleging it received kickbacks from Novartis Pharmaceuticals Corp. to push patients to continue using Novartis'...To view the full article, register now.
Already a subscriber? Click here to view full article